Current treatment for Ewing’s sarcoma

@article{Thacker2005CurrentTF,
  title={Current treatment for Ewing’s sarcoma},
  author={Mihir M. Thacker and Harry Thomas Temple and Sean P. Scully},
  journal={Expert Review of Anticancer Therapy},
  year={2005},
  volume={5},
  pages={319 - 331}
}
Ewing’s sarcoma is the second most common primary bone tumor seen in children and adolescents, and was described by James Ewing in 1921 as a diffuse endothelioma of bone. It is one of the differential diagnoses of pediatric small round blue cell tumors. This is not a single condition, but a group of morphologically and clinically closely related disorders with similar molecular biology – expression of tumor-specific chimeric oncoproteins through balanced chromosomal translocations involving the… Expand
Ewing Sarcoma Family of Tumors
TLDR
Because most patients with clinically apparent localized disease at diagnosis may also have occult metastatic (ie, systemic) disease, multidrug chemotherapy as well as local disease control with surgery and/or radiation therapy are indicated for all patients. Expand
Ewing Sarcoma: Focus on Medical Management
TLDR
Ewing sarcoma, a rare malignancy with a strong pediatric predilection, typically presents as a bone tumor and is the second most common primary malignant bone tumor in children and young adults. Expand
A 9-Year Old Girl with Metastatic Ewing's Sarcoma
TLDR
A patient diagnosed with Ewing’s sarcoma that involved right femur, cruris, pelvic and right frontal bone and Chemotherapy was done with four drug regimen (VACD) and gave significant progress of patient condition. Expand
Pediatric Sarcomas.
TLDR
Current regimens focus on decreasing treatment for low-risk patients to decrease the long-term side effects while maximizing therapy for patients with metastatic disease to improve survival. Expand
The Biology of Ewing Sarcoma
TLDR
Preclinical evidence suggests the utility of molecular therapies for Ewing sarcoma, and early clinical results reveal potential for novel treatments but require further development and evaluation before widespread use can be advocated. Expand
Primary intracranial dural-based Ewing sarcoma/peripheral primitive neuroectodermal tumor mimicking a meningioma: A rare tumor with review of literature
TLDR
It is found that most cases of ES involving CNS represent secondary metastases from extracranial sites of ES/ pPNET and there are rare case reports of primary intracranial ES-pPNET. Expand
Ewing sarcoma of the liver with multilocular cystic mass formation: a case report
TLDR
Clinicians should consider the possibility of Ewing sarcoma in young patients with a multilocular cystic mass with thick and/or irregular cyst walls in the liver with no evidence of recurrence 15 months after completing chemotherapy. Expand
The Genomic Landscape of Pediatric Bone Sarcomas
TLDR
While osteosarcomas and Ewing’s sarcomas occur in similar anatomic locations, they are vastly different from one another based on their genotypes. Expand
Management of Primitive Neuro-ectodermal Tumor of the Vagina in a Sickle Cell Disease Patient
Primitive neuro-ectodermal tumor (PNET) is rare comprising 1% of soft tissue sarcomas. PNET is considered an entity of Ewing’s family of tumors. Ewing’s family of tumors is not a single condition butExpand
Extra-skeletal Ewing's sarcoma in adults: presentation of two cases.
TLDR
Two cases in adult patients are presented, emphasizing the complexity of a multi-modality treatment approach of this tumour, and clinical presentation, chemotherapeutic, surgical and radiotherapeutical approaches are discussed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 136 REFERENCES
Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?
  • B. Druker
  • Medicine, Biology
  • Journal of the National Cancer Institute
  • 2002
TLDR
The data quite strongly imply that c-KIT is not the primary target for imatinib in Ewing’s sarcoma cells and lead to the inescapable conclusion that expression of c- kIT does not equate with a critical role for c- KIT in the growth and survival of Ewing's sarcomA cells. Expand
Treatment of Ewing sarcoma family of tumors: current status and outlook for the future.
TLDR
Future treatment for Ewing sarcoma family of tumors should consider risk-adapted strategies and the inclusion of newer therapies such as biologic modifiers for the minimal residual disease. Expand
Ewing’s Sarcoma and the Development of Secondary Malignancies
TLDR
Although the risk of having secondary malignancy develop after the treatment of a Ewing’s sarcoma may be only slightly greater than the risk compared with other childhood cancers, patients with hematopoietic and radiation-induced secondarymalignancies have a detrimental prognosis. Expand
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
TLDR
The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcomeFor patients with nonmetastatic Ewing's Sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone. Expand
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.
TLDR
Fifty-two percent of CESS 86 patients survived after risk-adapted therapy, and high-risk patients seem to have benefited from intensified treatment that incorporated ifosfamide, in multivariate analyses. Expand
Ewing's sarcoma: surgical resection as a prognostic factor.
TLDR
Surgical resection when added to local irradiation has prognostic significance in this retrospective review, but may be related to a decrease in local failure after resection. Expand
Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities.
  • P. Picci, T. Böhling, +17 authors F. Bertoni
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
TLDR
The proposed histopathologic grading, to evaluate the effect of chemotherapy on the primary tumor, had the strongest correlation to clinical outcome and could therefore be used to identify patients with a high risk of recurrent disease. Expand
Ewing's sarcoma of the pelvis: changes over 25 years in treatment and results.
TLDR
The purpose of the present study was to investigate the impact of newer chemotherapy schedules, improved radiotherapy techniques and newer surgical methods on the prognosis of Ewing's sarcoma and to analyse treatment results over a period of 25 years. Expand
Long-Term Follow-Up and Prognostic Factors in Ewing’s Sarcoma
TLDR
In conclusion, one third of patients with Ewing’s sarcoma become long-term survivors with combined modality treatment, and the value of serum albumin warrants confirmatory studies. Expand
Role of surgical resection in pelvic Ewing's sarcoma.
TLDR
Currently, morbidity of surgical resection should be weighed against the efficacy and secondary complications of radiation therapy in the decision-making process for local disease control in patients who undergo resection. Expand
...
1
2
3
4
5
...